The DOI matches its Crossref record.
Prevalence of a Putative Efflux Mechanism among Fluoroquinolone-Resistant Clinical Isolates of Streptococcus pneumoniae
Open accessAbstract
Twenty-three norfloxacin-selected first-step mutants of Streptococcus pneumoniae showed low-level fluoroquinolone resistance. Their susceptibility to norfloxacin in the presence or absence of reserpine and known efflux pump substrates was determined by an agar dilution method. Five mutants showed four- to eightfold increases in their susceptibility to norfloxacin in the presence of reserpine and four- to eightfold decreases in their susceptibility to acriflavine and ethidium bromide. This phenotype is suggestive of an efflux mechanism of resistance. A representative of these mutants, 1N27, accumulated significantly less ethidium bromide than the parent strain; reserpine abolished these differences. No changes in the quinolone resistance-determining regions of parC , parE , gyrA , or gyrB were found in this mutant. By our validated agar dilution method, the efflux phenotype was sought in clinical isolates of S. pneumoniae . Of 1,037 clinical isolates examined from the United Kingdom, 273 showed reduced susceptibility to norfloxacin or ciprofloxacin. Of these, 45.4% showed the efflux phenotype. Our findings suggest that an efflux mechanism may be a frequent cause of clinically significant fluoroquinolone resistance in pneumococci.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Clinically Relevant Chromosomally Encoded Multidrug Resistance Efflux Pumps in Bacteria
Piddock, L. J. V. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.2.382-402.2006 · Cited by 1,231
Efflux-Mediated Drug Resistance in Bacteria
Li, X.-Z., & Nikaido, H. (2004) · Drugs · doi:10.2165/00003495-200464020-00004 · Cited by 798
Molecular Properties of Bacterial Multidrug Transporters
Putman, M., van Veen, H. W., & Konings, W. N. (2000) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.64.4.672-693.2000 · Cited by 795
Molecular Detection of Antimicrobial Resistance
Fluit, A. C., Visser, M. R., & Schmitz, F.-J. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.836-871.2001 · Cited by 525
Mechanisms of fluoroquinolone resistance
Hooper, D. C. (1999) · Drug Resistance Updates · doi:10.1054/drup.1998.0068 · Cited by 488
Van Bambeke, F., Balzi, E., & Tulkens, P. M. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00291-4 · Cited by 404
Fluoroquinolones, tuberculosis, and resistance
Ginsburg, A. S., Grosset, J. H., & Bishai, W. R. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00671-6 · Cited by 403
A Critical Review of the Fluoroquinolones: Focus on Respiratory Infections
Zhanel, G. G., Ennis, K., Vercaigne, L., Walkty, A., Gin, A. S., Embil, J., Smith, H., & Hoban, D. J. (2002) · Drugs · doi:10.2165/00003495-200262010-00002 · Cited by 344
Van Bambeke, F., Michot, J.-M., Van Eldere, J., & Tulkens, P. M. (2005) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01131.x · Cited by 342
Role of mycobacterial efflux transporters in drug resistance: an unresolved question
Rossi, E. D., Aínsa, J. A., & Riccardi, G. (2006) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2005.00002.x · Cited by 328
Mechanisms of Fluoroquinolone Resistance: An Update 1994-1998
Piddock, L. J. V. (1999) · Drugs · doi:10.2165/00003495-199958002-00003 · Cited by 308
Renau, T. E., Léger, R., Flamme, E. M., Sangalang, J., She, M. W., Yen, R., Gannon, C. L., Griffith, D., Chamberland, S., Lomovskaya, O., et al. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm9904598 · Cited by 260
Gill, M. J., Brenwald, N. P., & Wise, R. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.1.187 · Cited by 259
Self-citation
Metadata
- Authors
- Brenwald, N. P., Gill, M. J., & Wise, R.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1998-08
- Volume
- 42
- Issue
- 8
- Pages
- 2032-2035
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2152166532
- Cited by
- 202
- References
- 0
- FWCI
- 9.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.